4 results about "Burningbush" patented technology

This invention belongs to the field of traditional Chinese medicine technology, specifically relating to a traditional Chinese medicine composition, preparation, preparation method, and application for treating polycystic ovary syndrome (PCOS). The traditional Chinese medicine composition for treating PCOS comprises the following raw materials in parts by weight: 10-15 parts of Cuscuta chinensis, 10-15 parts of Lycium barbarum, 10-20 parts of Taxillus chinensis, 10-15 parts of Angelica sinensis, 10-15 parts of Achyranthes bidentata, 10-15 parts of Ligusticum chuanxiong, 10-15 parts of Alisma plantago-aquatica, 10-15 parts of Nelumbo nucifera leaf, 10-15 parts of Gynostemma pentaphyllum, 10-20 parts of Salvia miltiorrhiza, 5-10 parts of Euonymus alatus, 5-10 parts of Coptis chinensis, and 5-10 parts of Glycyrrhiza uralensis. Its core treatment principle is to tonify the kidney and spleen, promote blood circulation, and resolve phlegm, and it is used to treat PCOS.

This invention belongs to the field of biotechnology, specifically relating to neuropeptides from the root-knot nematode *Euonymus alatus*. nlp12 Genes, their dsRNAs, and applications. To provide novel target genes for the control of *Heliotropium indicum* root-knot nematodes, this invention is based on... nlp12 The nucleotide sequence of the gene is SEQ ID NO:1. Gene fragment SEQ ID NO:5 and the corresponding dsRNA were designed and synthesized. The synthesized dsRNA was used to soak second-instar root-knot nematodes. nlp12 Gene expression levels were downregulated, resulting in a mortality rate of 73.2% at 60 hours, and complete mortality of nematodes at 108 hours. Immersion nlp12 The dsRNA-infected second-instar larvae of the bean root-knot nematode significantly reduced the infectivity of tomato roots. After 30 days of inoculation, the number of root knots decreased significantly by about 54%, and the number of female nematodes, the number of egg masses, the number of eggs in each egg mass, and reproductive factors were all significantly reduced.

This invention discloses a traditional Chinese medicine composition for treating cerebrovascular diseases, belonging to the technical field of cerebrovascular disease drugs. The composition comprises the following components in parts by weight: 10-30 parts of Polygonatum sibiricum, 6-15 parts of Rosa laevigata, 6-12 parts of Euonymus alatus, 6-15 parts of Polygonum cuspidatum, 3-9 parts of Acorus tatarinowii, 3-10 parts of Alpinia oxyphylla, 3-6 parts of Aralia elata septum, 3-10 parts of Rhodiola rosea, 3-10 parts of Bletilla striata, and 1-6 parts of Cinnamomum cassia. This invention addresses the pathological characteristics of cerebrovascular diseases, including long disease courses, multiple risk factors, and involvement of multiple target organs. Through the systematic combination of ten herbs, it can simultaneously achieve cerebrovascular protection, nerve function repair, and protection against multi-organ damage. Animal experiments and clinical observations have confirmed that this composition can significantly improve patients' neurological deficit scores, reduce the incidence of complications, and has clear preventive and therapeutic effects on secondary complications such as stress ulcers and renal impairment, while also possessing antithrombotic and hemostatic properties and high safety.

This invention relates to a traditional Chinese medicine composition for delaying the progression of kidney deficiency and blood stasis syndrome in diabetic nephropathy, its application, and preparation method. The composition is made from Astragalus membranaceus, Salvia miltiorrhiza, Paeonia lactiflora, Anemarrhena asphodeloides, Phellodendron chinense, Cistanche deserticola, Scutellaria baicalensis, Euonymus alatus, Schisandra chinensis, raw oyster shell, Plantago asiatica, and Artemisia annua. It has the effects of nourishing the kidneys, clearing heat, eliminating toxins, and unblocking the meridians. This traditional Chinese medicine composition can effectively delay the decline in renal function in patients with massive proteinuria during the diabetic nephropathy stage, improve the clinical symptoms of patients with kidney deficiency and blood stasis syndrome, and improve their quality of life. Simultaneously, it has a low risk of hyperkalemia and gastrointestinal bleeding, and no significant damage to liver function has been observed, indicating high safety.